© 2008, Columbia Laboratories, Inc. All rights reserved.

 

Please note that the product information provided on this website is intended only for residents of the United States.

In IVF-ET cycles—

 

Pregnancy Rates Comparable to IM Progesterone1

 

Study design: Results of a retrospective analysis of 1675 IVF-ET cycles in which women received progesterone for luteal phase support. Patients received Crinone 8% (90 mg QD), progesterone vaginal suppositories (100 mg QD), or IM progesterone (50 mg QD). Progesterone support started on the day after oocyte retrieval and continued through 7–10 weeks in case of pregnancy.

 

Crinone 8% usage more than doubled during this retrospective study

  • Usage increased from 21.7% in the 1st quarter to 50.1% by the 4th quarter
  • Type of progesterone was determined by patient and physician preference

Reference: 1. Alper MM, Penzias AS. Crinone® offers excellent implantation rates in patients undergoing IVF. Paper presented at the 16th Annual Meeting of the European Society for Human Reproduction & Embryology; June 2000; Bologna, Italy. Abstract P-059.